Core Viewpoint - The company achieved a significant turnaround in its financial performance for the fiscal year ending December 31, 2024, with a net profit of 33.54 million yuan, marking a return to profitability after a previous loss [1][2] Financial Performance - The company's revenue reached 980 million yuan, representing a year-on-year growth of 36.8% [1] - The earnings per share for the year were 0.08 yuan, indicating a successful recovery [1] - The antibody discovery business generated revenue of 317.8 million yuan, an increase of 80.7% compared to the previous year, accounting for 32.4% of total revenue [1] Strategic Developments - The company signed approximately 200 drug collaboration/authorization/transfer agreements, with about 100 new agreements signed in 2024, reflecting a growth of approximately 70% year-on-year [1] - The company has established a global network, particularly with advanced laboratory facilities in Boston, contributing to the rapid growth of its model animal and antibody discovery businesses [2] Cost Management - Research and development expenses decreased to 323.9 million yuan, down approximately 31.7% from the previous year, indicating a shift in focus towards long-term development [2] - General and administrative expenses were reduced to 218.4 million yuan, a decrease of about 23.7%, showcasing improved operational efficiency [2]